On April 20, 2020 Qiuzhen Medical Technology (Beijing) Co., Ltd. (referred to as: Qiuzhen Medical) reported that it has received hundreds of millions of yuan in B-round financing (Press release, ChosenMed Technology, APR 20, 2020, View Source [SID1234556519]). Last-round investors such as Fang Capital and Data Capital continued to follow suit. This round of financing is mainly used for the registration of tumor multi-gene testing products and the industrialization of IVD. It will continue to promote the intelligentization of tumor companion diagnostic testing and data analysis, and continue to create a closed loop for precision medical treatment of tumors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Qiuzhen Medical previously completed nearly RMB 100 million in angel rounds and round A financing in 2018.

Based on bioinformatics and high-throughput sequencing technology, Qiuzhen Medical has a comprehensive layout in the field of tumor liquid biopsy. It has original tumor detection products in multiple market segments and meets clinical needs. The products cover early cancer screening and targeted drug concomitant The fields of diagnosis, immunoassay, dynamic monitoring, prognosis assessment and tumor bioinformatics big data platform analysis.

Exploring technological innovation and striving for medical excellence

Since the establishment of Qiuzhen Medicine, it has rapidly arranged the upstream and downstream of the industry chain, actively introduced top teams of scientists at home and abroad, and continued to increase investment in research and development. After three years of rapid development, Qiuzhen Medical has owned a number of business lines such as third-party medical testing services, IVD (in vitro diagnostic) product production, and oncology medical big data platforms. Strategic cooperation.

At present, Qiuzhen Medical has independently developed more than 20 tumor detection products covering pan-cancer, lung cancer and other nine systemic tumors. Among them, ChosenOne 599, ChosenLung and other products have been awarded the title of new technology and new products (services) in Beijing. For the above products, Qiuzhen Medicine has provided accurate tumor gene testing services for hundreds of cancer specialists and general hospitals in China, and has won unanimous recognition and praise from doctors and patients.

Qiuzhen Medical now has 34 patents and 54 scientific and technological achievements based on the Big Panel’s Shengxin Software copyrights, and has won the "Top 50 Most Valuable Enterprises in China", "Top 100 Chinese Innovative Growth Enterprises", and "Deloitte-Yizhuang Honorable qualifications such as "Tomorrow Star", "Top 100 Medical Future List", "Postdoctoral Research Station".

Undertake "China Cancer Gene Atlas Project" (CGAC project) and high-tech industry to collaboratively innovate oncology precision medicine big data platform

Qiuzhen Medicine is the only corporate legal entity that cooperates with the China Cancer Gene Atlas Project (CGAC Project). It will work with more than 70 domestic top three hospitals to collect and test more than 10,000 tumor samples, and jointly design and establish a Chinese tumor gene database and clinical The database actively promotes the expert consensus of the Panel on Multi-gene Cancer Detection, and will build a tumor sample database based on the Chinese population in the future to provide sample data support for the research and development and clinical research of tumor drugs and accompanying diagnostic kits.

In order to continue to promote the storage and detection of tumor biological samples, the construction of storage of clinical data such as patient basic information, clinical treatment programs, etc., based on its own scientific research products, Qiuzhen Medicine will rely on its internationally leading biological information analysis platform and algorithm in October 2019. In July, the company launched its own medical information platform with its own intellectual property rights. Through this platform, it has provided more than 40 companies with data storage, data query, biological information analysis and other services. At the same time, it has served many companies to complete tumor genetic testing. Analytical statistical services, sample testing services, and new analytical algorithm development services.

In the future, Qiuzhen Medicine will continue to improve the oncology precision medicine big data platform, and work with more than 70 domestic top three hospitals to jointly design and establish a Chinese tumor gene database and clinical database; top experts from institutions such as the United Nations Human Genetic Resource Center and establish expert committees To focus on solving common technical problems in the construction of oncology precision medicine big data platforms, especially to propose solutions for the standardization of the detection process and the development of bioinformatics algorithms.

Mr. Sun Dawei, Chairman of Qiuzhen Medical, said: "We are very honored to receive the trust and support of well-known investment institutions and all old shareholders. As a high-tech company focused on the field of oncology precision medicine, Qiuzhen Medical has always been committed to the transformation of advanced scientific and technological achievements. To provide the best quality products and services for clinicians and patients. In the future, we will unswervingly exert our own advantages, increase independent research and development, continue to launch competitive and innovative products, and advance China’s tumor precision medical industry to a new Steps! "

Mr. Liu Yujia of Shanghai Lianhe, the leading investor, said: "Quzhen Medical has an international top technical team, which makes it unique in the field of bioinformatics analysis, and integrates technology research and development, market expansion, and clinical registration. The ability is becoming more and more obvious. Lianhe Investment is very optimistic about the team of Qizhen. Investing in Qizhen is full of confidence in the future of Qizhen. We will be very determined to join hands and seek common development. "

Honghui Capital spokesperson Ms. Jiang Yanye said: "Honghui Capital, as an old shareholder, reinvests again, not only optimistic about the outstanding achievements of Qiuzhen Medical in all aspects, but also very much appreciates its open and inclusive, large-scale corporate feelings, regardless of its participation The national project undertaken-"China Cancer Gene Atlas Project", is committed to filling the gaps in China’s cancer gene atlas, or is the rapid development in the market. We believe that Qiuzhen Medicine will make greater progress in the field of tumor precision medicine. "

Mr. Zhu Jia of Heyahua Medicine said: "As a professional medical investment fund, Heyahua Medicine is very optimistic about the track in the field of precision medicine for tumors, especially high-tech such as Qiuzhen Medicine that has achieved excellent results in the field of precision medicine for tumors. Company. I hope that Qiuzhen Medical will continue to make steady progress with the team’s international vision and excellent execution ability, and continue to make new breakthroughs. "